• Home
  •  / Radius Health

Radius Health

OverviewSuggest Edit

Radius is a leading company in the discovery and development of a new generation of drug therapies for osteoporosis and women's health. The Сompany's first drug in clinical trials is designed to build new bone in patients with osteoporosis, with the goal of reducing the risk of future fractures and improving the quality of life. Their long-term focus is on additional areas in women's health that include symptoms of menopause, reproductive disorders, and frailty associated with aging.

TypePublic
Founded2003
HQWaltham, USMap
Websiteradiuspharm.com
Employee Ratings2.9More
View Jobs (11)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)383(-3%)
Job Openings11
Revenue (FY, 2017)$12.1 M
Share Price (Oct 2020)$13.8 (+2%)
Cybersecurity ratingAMore

Key People/Management at Radius Health

Sal Grausso

Sal Grausso

Chief Commercial Officer
Kelly Martin

Kelly Martin

President and Chief Executive Officer
Jose Carmona

Jose Carmona

Chief Financial Officer
Charles Morris

Charles Morris

Chief Medical Officer
Averi Price

Averi Price

General Counsel and Chief Compliance Officer
Chhaya Shah

Chhaya Shah

Chief Business Officer
Show more

Radius Health Office Locations

Radius Health has offices in Waltham, Cambridge and Wayne
Waltham, US (HQ)
950 Winter St
Cambridge, US
237 Putnam Ave
Wayne, US
CrossPoint at Valley Forge, 550 Swedesford Rd #370
Show all (3)

Radius Health Financials and Metrics

Radius Health Revenue

Radius Health's revenue was reported to be $12.11 m in FY, 2017
USD

Revenue (Q2, 2020)

50.1m

Net income (Q2, 2020)

(43.9m)

EBIT (Q2, 2020)

(37.3m)

Market capitalization (23-Oct-2020)

640.4m

Closing stock price (23-Oct-2020)

13.8

Cash (30-Jun-2020)

56.2m

EV

600.9m
Radius Health's current market capitalization is $640.4 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

12.1m

Cost of goods sold

7.6m

General and administrative expense

5.3m9.5m6.8m13.7m30.8m77.5m186.7m184.2m152.7m

R&D expense

36.2m55.0m60.5m45.7m68.3m107.4m83.1m99.9m116.8m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

980.0k3.5m14.5m47.9m50.1m

Cost of goods sold

105.0k

Gross profit

875.0k

Gross profit Margin, %

89%
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

25.1m18.7m12.3m28.5m159.7m258.6m118.6m59.3m69.9m

Accounts Receivable

28.3m4.4m16.8m23.3m

Prepaid Expenses

6.7m2.5m334.0k2.1m7.0m5.2m13.8m12.1m

Inventories

2.3m4.4m6.2m5.3m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

25.3m19.9m18.0m18.8m20.4m13.4m24.8m19.5m29.6m48.4m16.5m34.8m44.4m168.7m104.4m120.6m198.6m174.6m135.1m446.9m56.1m51.4m62.0m71.5m66.9m88.9m40.7m56.2m

Accounts Receivable

1.2m11.7m8.0m11.0m12.9m20.8m23.6m21.5m30.4m17.9m

Prepaid Expenses

3.4m3.3m8.4m6.0m4.2m1.2m1.4m242.0k2.3m1.8m1.4m2.5m3.1m4.5m2.8m5.2m3.7m6.5m5.9m7.8m6.4m6.5m10.1m12.4m8.2m15.2m9.2m7.9m

Inventories

1.6m3.1m5.4m6.2m5.5m5.6m5.2m4.9m6.0m5.9m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(42.5m)(69.1m)(60.7m)(62.5m)(101.5m)(182.8m)(254.2m)(221.3m)(133.0m)

Depreciation and Amortization

40.0k44.0k27.0k77.0k176.0k586.0k2.0m2.9m2.3m

Inventories

(4.4m)(1.8m)887.0k

Accounts Payable

(301.0k)237.0k(250.0k)2.0m3.9m(100.0k)(2.2m)311.0k1.8m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(22.6m)(32.0m)(12.9m)(30.8m)(48.4m)(8.3m)(27.8m)(48.2m)(14.5m)(27.1m)(17.1m)(40.0m)(68.3m)(40.5m)(83.9m)(130.1m)(56.9m)(125.4m)(183.2m)(61.6m)(130.4m)(180.2m)(42.8m)(78.2m)(108.3m)(37.7m)(81.5m)

Depreciation and Amortization

15.0k23.0k14.0k24.0k33.0k13.0k13.0k21.0k16.0k33.0k36.0k78.0k126.0k96.0k216.0k371.0k252.0k695.0k1.4m671.0k1.3m2.0m633.0k1.2m1.8m492.0k945.0k

Inventories

(1.6m)(3.1m)(1.1m)(1.9m)(1.2m)564.0k1.1m1.3m(679.0k)(583.0k)

Accounts Payable

(541.0k)1.4m690.0k934.0k549.0k887.0k1.0m2.1m(21.0k)888.0k1.3m881.0k999.0k2.2m(2.4m)(3.2m)(3.6m)599.0k(1.7m)(2.4m)610.0k(1.4m)2.4m5.7m1.8m382.0k3.2m5.7m
show all
USDQ2, 2011

Financial Leverage

-0.3 x
Show all financial metrics

Radius Health Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

Learn more about about our premium products
SecurityScorecard logo

Radius Health Online and Social Media Presence

Radius Health's Trends

Embed Graph

Radius Health News and Updates

October 21, 2020

Radius Health, Inc.: Progress Since May 2020

WALTHAM, Mass., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) provided a general business update on progress made since May 2020. The Company will provide further updates during its third quarter earnings call and at subsequent investor conference…
October 21, 2020

Sarcopenia Treatment Market Future Prospects 2027 with Leading Key Insights – Radius Health, Cadila Healthcare, GlaxoSmithKline

Sarcopenia is a situation characterized by a loss of skeletal muscle mass and function. Sarcopenia is a syndrome characterized by progressive and generalized loss of skeletal muscle mass and strength, and it is strictly correlated with a physical disability, poor quality of life, and death. Posted v…
October 01, 2020

Radius Health Divests RAD 140 Program to Ellipses Pharma

WALTHAM, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS) announced today that the company has successfully sold its second oncology pipeline asset – RAD 140 - to Ellipses Pharma Limited, completing Radius’s divestment of its oncology assets. Under the agreement, Ellipse…
September 27, 2020

Radius Health & Menarini-Gruppe liefern Elacestrant Update

Zielrekrutierungs-Meilenstein in der Phase-3-EMERALD-Studie erreicht Nutzungsdauerplanung schreitet parallel zum laufenden Monotherapieprogramm der Phase 3 voran WALTHAM, Mass. und FLORENCE, Italien, 27. September 2020 /PRNewswire/ -- Radius Health, Inc. („Radius" oder das „Unternehmen")...
September 27, 2020

A Radius Health e o Grupo Menarini fazem atualização do Elacestrant

WALTHAM, Massachusetts e FLORENÇA, Itália, 27 de setembro de 2020 /PRNewswire/ -- A Radius Health, Inc. ("Radius" ou a "Empresa") (Nasdaq: RDUS) e o Grupo Menarini anunciaram hoje uma atualização da Fase 3 do estudo clínico EMERALD do elacestrant. FASE 3 DO ESTUDO EMERALD O marco de...
September 26, 2020

Radius Health y el Grupo Menarini actualizan la información sobre elacestrant

Se alcanza el reclutamiento meta en el estudio de fase 3 EMERALD La planificación del ciclo de vida avanza en paralelo con el actual programa de monoterapia de fase 3 WALTHAM, Massachusetts y FLORENCIA, Italia, 26 de septiembre de 2020 /PRNewswire/ -- Radius Health, Inc. (Nasdaq: RDUS) y...
Show more

Radius Health Blogs

August 25, 2020

Radius Health Provides Business Update

TYMLOS ® patent extended to 2031, adding approximately 3½ years to the TYMLOS-SC patent life Enrollment completed for ATOM Phase 3 study assessing the efficacy and safety of abaloparatide-SC in males with osteoporosis WALTHAM, Mass. , Aug. 25, 2020 (GLOBE NEWSWIRE) -- Radius Health , Inc. (“Radius”
August 10, 2020

Sean Murphy joins Radius Health Board of Directors

WALTHAM, Mass. , Aug. 10, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced the appointment of Sean Murphy to its Board of Directors with immediate effect. Sean has several decades of experience in the industry across pharmaceuticals,
July 27, 2020

Radius Health to Announce Second Quarter 2020 Financial Results, Host Conference Call and Live Webcast on Monday, August 10, 2020

WALTHAM, Mass. , July 27, 2020 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its second quarter financial results on Monday, August 10, 2020 . The Company will host a conference call and live audio webcast at 8:30 a.m.
July 23, 2020

Menarini Group and Radius Health Announce Global License Agreement for the Development and Commercialization of Elacestrant

Menarini Group and Radius Health Announce Global License Agreement for the Development and Commercialization of Elacestrant Content Import Thu, 07/23/2020 - 16:16 Menarini Group and Radius Health Announce Global License Agreement for the Development and Commercialization of Elacestrant …
May 07, 2020

Radius Health Announces First Quarter 2020 Operating Results

TYMLOS® U.S. net sales of $48 million, with 61% year over year growth Our three Phase 3 studies continue to advance amid slowdown in recruitment due to COVID-19 pandemic. Anticipated data read-outs remain on track for second half of 2021 Due to anticipated impact of pandemic, 2020 TYMLOS U.S.
April 28, 2020

Radius Health Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass. , April 28, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS) today announced that the Company’s Board of Directors (the “Board”) granted G. Kelly Martin , in connection with his appointment as Chief Executive Officer and President of the Company,
Show more

 Radius Health Frequently Asked Questions

  • When was Radius Health founded?

    Radius Health was founded in 2003.

  • Who are Radius Health key executives?

    Radius Health's key executives are Sal Grausso, Kelly Martin and Jose Carmona.

  • How many employees does Radius Health have?

    Radius Health has 383 employees.

  • Who are Radius Health competitors?

    Competitors of Radius Health include Inovio Pharmaceuticals, Genprex and TG Therapeutics.

  • Where is Radius Health headquarters?

    Radius Health headquarters is located at 950 Winter St, Waltham.

  • Where are Radius Health offices?

    Radius Health has offices in Waltham, Cambridge and Wayne.

  • How many offices does Radius Health have?

    Radius Health has 3 offices.